Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Interventional × Rare Tumour × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 363 Neoplasms 264 Carcinoma, Non-Small-Cell Lung 238 Colorectal Neoplasms 196 Lung Neoplasms 152 Prostatic Neoplasms 149 Carcinoma, Hepatocellular 129 Stomach Neoplasms 121 Multiple Myeloma 106 Pancreatic Neoplasms 95 Leukemia, Myeloid, Acute 95 Uterine Cervical Neoplasms 83 Recurrence 83 Rectal Neoplasms 80 Squamous Cell Carcinoma of Head and Neck 77 Neoplasm Metastasis 72 Small Cell Lung Carcinoma 68 Ovarian Neoplasms 68 Brain Neoplasms 65 Triple Negative Breast Neoplasms 61 Glioblastoma 61 Head and Neck Neoplasms 59 Esophageal Neoplasms 55 Endometrial Neoplasms 51 Colonic Neoplasms 51 Precursor Cell Lymphoblastic Leukemia-Lymphoma 47 Glioma 45 Anxiety Disorders 45 Motor Activity 44 Hematologic Neoplasms 41

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡